Department of Orthopaedic Surgery, Shuwa General Hospital, 1200, Yawarasinden, Kasukabe, Saitama 344-0035, Japan.
Mod Rheumatol. 2012 Feb;22(1):147-51. doi: 10.1007/s10165-011-0483-y. Epub 2011 Jul 20.
We describe 3 cases of rheumatoid arthritis presenting with elevated serum KL-6 levels during treatment with adalimumab, which was discontinued because of suspected onset of complications. However, no complications were observed following discontinuation despite comprehensive assessments, and KL-6 levels subsequently returned to baseline levels. In our institutes, 3 out of 29 cases treated with adalimumab showed elevated KL-6 levels. The baseline levels were 445, 347, and 547 U/ml, while the peak levels were 1010, 546, and 2007 U/ml, respectively. The elevated KL-6 levels seem to have been innocuous; nevertheless, further careful observation is deemed necessary.
我们描述了 3 例类风湿关节炎患者在接受阿达木单抗治疗期间出现血清 KL-6 水平升高的情况，由于怀疑出现并发症而停用了该药。然而，尽管进行了全面评估，停药后并未观察到任何并发症，并且 KL-6 水平随后恢复至基线水平。在我们的医院中，29 例接受阿达木单抗治疗的患者中有 3 例出现 KL-6 水平升高。基线水平分别为 445、347 和 547 U/ml，而峰值水平分别为 1010、546 和 2007 U/ml。升高的 KL-6 水平似乎没有危害，但仍需进一步仔细观察。
